Cargando…

Tumour necrosis factor-alpha, interleukin-2 soluble receptor and different inflammatory parameters in patients with rheumatoid arthritis.

BACKGROUND AND AIMS: Although the participation of cytokines in the pathogenesis of rheumatoid arthritis (RA) seems to be unequivocal, their relationship with current serum markers of this disease is not clear. The present study analyses whether there is any correlation between the levels of tumour...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fröde, Tânia Silvia, Tenconi, Patrícia, Debiasi, Marilei Reynaud, Medeiros, Yara Santos
Formato:	Texto
Lenguaje:	English
Publicado:	2002
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781685/ https://www.ncbi.nlm.nih.gov/pubmed/12581498 http://dx.doi.org/10.1080/0962935021000051539

Ejemplares similares

Evaluation of Tumour Necrosis Factor Alpha, Interleukin-2 Soluble Receptor, Nitric Oxide Metabolites, and Lipids as Inflammatory Markers in Type 2 Diabetes Mellitus
por: Pereira, Flávia Ozorio, et al.
Publicado: (2006)

Proinflammatory Soluble Interleukin-15 Receptor Alpha Is Increased in Rheumatoid Arthritis
por: Machado Diaz, Ana Cecilia, et al.
Publicado: (2012)

Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
por: Glossop, John R, et al.
Publicado: (2005)

Salivary interleukin 6, interleukin 8, interleukin 17A, and tumour necrosis factor α levels in patients with periodontitis and rheumatoid arthritis
por: Kaczyński, Tomasz, et al.
Publicado: (2019)

Overnight variations in cortisol, interleukin 6, tumour necrosis factor α and other cytokines in people with rheumatoid arthritis
por: Perry, M G, et al.
Publicado: (2009)

Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.
por: Miles, D. W., et al.
Publicado: (1992)

Anti-tumour necrosis factor alpha treatment in patients affected by rheumatoid arthritis with anti-Ro/SSA antibodies
por: Cavazzana, I, et al.
Publicado: (2005)

Induction of tumour necrosis factor receptor-expressing macrophages by interleukin-10 and macrophage colony-stimulating factor in rheumatoid arthritis
por: Takasugi, Koji, et al.
Publicado: (2006)

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Therapeutic inhibition of tumour necrosis factor alpha reduces oligoclonality in the selected T-cell receptor BV families in rheumatoid arthritis
por: Pierer, M, et al.
Publicado: (2003)

Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis
por: Stavropoulos-Kalinoglou, Antonios, et al.
Publicado: (2012)

Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
por: Leandro, Maria J
Publicado: (2009)

Tumour necrosis factor-alpha and interleukin-8 inhibit neutrophil migration in vitro and in vivo
por: Cunha, F. Q., et al.
Publicado: (1992)

Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis
por: Takei, Satoko, et al.
Publicado: (2011)

Effects of methotrexate upon inflammatory parameters induced by carrageenan in the mouse model of pleurisy.
por: Dalmarco, Eduardo Monguilhott, et al.
Publicado: (2002)

Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
por: Robak, T, et al.
Publicado: (1998)

Characterization and Function of Tumor Necrosis Factor and Interleukin‐6–Induced Osteoclasts in Rheumatoid Arthritis
por: Yokota, Kazuhiro, et al.
Publicado: (2021)

Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis
por: Yang, Nicole, et al.
Publicado: (2019)

Inhibitory effects of bisbenzylisoquinolines on synthesis of the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha
por: Seow, W. Kim, et al.
Publicado: (1993)

Nardilysin is involved in autoimmune arthritis via the regulation of tumour necrosis factor alpha secretion
por: Fujii, Takayuki, et al.
Publicado: (2017)

Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor
por: Ernestam, Sofia, et al.
Publicado: (2006)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Interleukin 6 and Rheumatoid Arthritis
por: Yoshida, Yuji, et al.
Publicado: (2014)

Interleukin-6 in Rheumatoid Arthritis
por: Pandolfi, Franco, et al.
Publicado: (2020)

Tumour necrosis factor-alpha enhances the cytolytic and cytostatic capacity of interleukin-2 activated killer cells.
por: Matossian-Rogers, A., et al.
Publicado: (1989)

Effect of Exercise Training on Interleukin-6, Tumour Necrosis Factor Alpha and Functional Capacity in Heart Failure
por: Smart, Neil A., et al.
Publicado: (2011)

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
por: Alonso-Ruiz, Alberto, et al.
Publicado: (2008)

Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy
por: Leboime, Ariane, et al.
Publicado: (2009)

Tumor Necrosis Factor-Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis: A Systematic Review
por: Nair, Shaalina, et al.
Publicado: (2022)

Effect of soluble interleukin-6 receptor alpha and interleukin-6 secreted by polymorphonuclear leukocytes on tumor necrosis factor-alpha expression and its production by peripheral blood mononuclear cells.
por: Jablonska, E
Publicado: (2002)

Inhibition of tumour necrosis factor alpha production by activated T cells of rheumatoid arthritis patients by novel anti-folate drugs: an ex vivo pilot study
por: van der Heijden, JW, et al.
Publicado: (2005)

Anti-tumour necrosis factor therapy modulates the OPG/OPGL system in rheumatoid arthritis synovium
por: Catrina, AI, et al.
Publicado: (2004)

Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis
por: Massey, Jonathan, et al.
Publicado: (2018)

Correlation of serum tumor necrosis factor-alpha, interleukin-4 and soluble interleukin-2 receptor levels with radiologic and clinical manifestations in active pulmonary tuberculosis.
por: Kart, Levent, et al.
Publicado: (2003)

The value of serum type II collagen epitope measurement in assessing early clinical response to treatment with anti-tumour necrosis factor alpha therapy in rheumatoid arthritis
por: Mullan, RH, et al.
Publicado: (2005)

Interleukin-7 deficiency in rheumatoid arthritis
por: Leonard, Warren J
Publicado: (2005)

Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis
por: Cacciapaglia, Fabio, et al.
Publicado: (2016)

Tumour Necrosis Factor-α Inhibition Improves Stroke Outcome in a Mouse Model of Rheumatoid Arthritis
por: Bonetti, N. R., et al.
Publicado: (2019)

Tumour necrosis factor gene polymorphisms in Egyptian patients with rheumatoid arthritis and their relation to disease activity and severity
por: Zaghlol, Heba M., et al.
Publicado: (2019)

Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis
por: Giollo, Alessandro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o8nc0m6m34eg9fn9a4n87r8q1f